ABSTRACT
A study of 27 manic-depressives (some with histories of up to 65 years' duration and 100 attacks) showed that it is a disorder from which the patient can make a complete recovery without any cognitive deterioration. Many of these patients have had courses of the traditional drug and physical treatments (including ECT) used in mental hospitals over the last half century. This indicates that such treatments themselves need not produce deterioration.
Subject(s)
Bipolar Disorder/psychology , Cognition Disorders/psychology , Adult , Aged , Bipolar Disorder/therapy , Electroconvulsive Therapy , Female , Follow-Up Studies , Humans , Lithium/therapeutic use , Male , Middle Aged , Psychological TestsABSTRACT
A double-blind study was carried out in 30 hospital out-patients suffering from moderate to severe neurotic anxiety to compare the efficacy and tolerance of alprazolam and placebo. Patients were allocated at random to receive alprazolam, in a dosage of 0.5 to 1 mg 3-times daily, or placebo over a 4-week period. The results of assessments using the Hamilton Anxiety Rating Scale and global impressions of response to treatment by both physician and patients showed alprazolam to be superior to placebo in the relief of symptoms. Side-effects were infrequent: only 3 of the 15 patients in the alprazolam group reported mild or moderate drowsiness.
Subject(s)
Anti-Anxiety Agents/therapeutic use , Anxiety Disorders/drug therapy , Benzodiazepines/therapeutic use , Adolescent , Adult , Alprazolam , Clinical Trials as Topic , Double-Blind Method , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Random AllocationSubject(s)
Mental Disorders/therapy , Puerperal Disorders/therapy , Adolescent , Adult , Female , Hospital Units , Hospitals, Psychiatric , Humans , Infant, Newborn , Mother-Child Relations , Neurotic Disorders/therapy , Personality Disorders/therapy , Pregnancy , Psychotic Disorders/therapy , Schizophrenia/therapyABSTRACT
A double-blind trial was carried out in 29 patients recently admitted to hospital with depressive illness to compare the effectiveness and side-effect liability of treatment with amoxapine and imipramine. Both drugs were given in a dosage of 25 mg 3-times daily over a period of 4 weeks, and patients' progress was assessed using psychiatric and psychological rating scales for depression. Although amoxapine and imipramine proved equally effective, response to amoxapine was quicker and appeared to have the same effect after 1 week as did imipramine after 2 weeks. In addition, dryness of the mouth was complained of most frequently by patients taking imipramine.
Subject(s)
Amoxapine/therapeutic use , Depression/drug therapy , Dibenzoxazepines/therapeutic use , Amoxapine/adverse effects , Double-Blind Method , Female , Humans , Imipramine/adverse effects , Imipramine/therapeutic use , Male , Middle Aged , Psychiatric Status Rating ScalesSubject(s)
Antidepressive Agents/therapeutic use , Age Factors , Female , Humans , Male , Sex FactorsABSTRACT
A factorial study was made of ratings on 51 depressed female patients of IMPS items related to depression. Four separate depressive factors that involved: (1) loss of motivation and energy; (2) feelings of depression and hopelessness; (3) feelings of guilt and sin; and (4) retarded behavior were obtained. Neither the patient's age nor the endogenous-neurotic distinction appeared to be important. A comparison of these results with other factorial studies of depression was made.
Subject(s)
Adjustment Disorders/diagnosis , Depression/diagnosis , Anxiety/complications , Aspirations, Psychological , Diagnosis, Differential , Fatigue/complications , Female , Guilt , Humans , Motivation , Psychiatric Status Rating ScalesABSTRACT
No adverse effects were observed in a series of patients in whom he levels of creatine phosphokinase (C.P.K.) were known to be raised and who received anaesthetics. The need to exercise caution in the interpretation of screening test results for C.P.K. activity before anaesthesia is stressed.
